Reaction
Immune-Mediated Lung Disease reporting signals
As of the last recalculation, Immune-Mediated Lung Disease appears in 1,725 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is NIVOLUMAB (PRR 148.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nivolumab | 706 | 148.5 | 149.6 |
| Ipilimumab | 362 | 127.8 | 128.9 |
| Pembrolizumab | 646 | 117.8 | 118.6 |
| Pemetrexed | 147 | 90.3 | 91.0 |
| Durvalumab | 123 | 78.5 | 79.0 |
| Pemetrexed Disodium | 191 | 67.9 | 68.2 |
| Carboplatin | 350 | 41.5 | 41.6 |
| Paclitaxel (Aibumin-Bound) | 214 | 35.7 | 35.8 |
| Lenvatinib | 90 | 34.9 | 35.0 |
| Atezolizumab | 103 | 34.0 | 34.1 |
| Paclitaxel | 221 | 30.7 | 30.8 |
| Cisplatin | 84 | 13.6 | 13.6 |
| Ganciclovir | 11 | 13.0 | 13.1 |
| Ganciclovir Sodium | 11 | 12.6 | 12.6 |
| Entecavir | 12 | 12.5 | 12.5 |
| Dexamethasone Sodium Phosphate | 10 | 11.9 | 12.0 |
| Febuxostat Tablets 40 Mg | 10 | 11.9 | 11.9 |
| Febuxostat Tablets 80 Mg | 10 | 11.9 | 11.9 |
| Bevacizumab | 94 | 9.6 | 9.6 |
| Piperacillin And Tazobactam | 10 | 9.5 | 9.5 |
| Cabozantinib | 37 | 9.5 | 9.5 |
| Granisetron Hydrochloride | 8 | 9.3 | 9.3 |
| Oxaliplatin | 52 | 8.7 | 8.7 |
| Granisetron | 7 | 8.1 | 8.1 |
| Linagliptin | 12 | 8.0 | 8.0 |
| Eplerenone | 8 | 7.6 | 7.6 |
| Piperacillin Sodium,Tazobactam Sodium | 16 | 7.3 | 7.3 |
| Fluorouracil Cream, 0.5% | 45 | 7.3 | 7.3 |
| Febuxostat | 10 | 7.2 | 7.2 |
| Fluorouracil | 45 | 7.2 | 7.2 |
| Axitinib | 11 | 6.9 | 6.9 |
| Fosaprepitant Dimeglumine | 7 | 6.2 | 6.2 |
| Encorafenib | 5 | 6.1 | 6.1 |
| Aprepitant | 9 | 5.9 | 5.9 |
| Trametinib | 11 | 5.5 | 5.5 |
| Gemcitabine | 16 | 4.9 | 4.9 |
| Fentanyl Citrate | 7 | 4.7 | 4.7 |
| Gemcitabine Hydrochloride | 20 | 4.6 | 4.6 |
| Olaparib | 7 | 4.0 | 4.1 |
| Osimertinib | 10 | 3.8 | 3.8 |